

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

INSIDE INFORMATION RECEIPT OF WRIT OF SUMMONS

This announcement is made by the board of directors of Yestar Healthcare Holdings Company Limited (“**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 8 November 2021, 3 December 2021, 12 December 2021, 14 December 2021, 29 December 2021, 31 December 2021 and 3 January 2023 relating to the 9.5% senior notes due 2026 issued by the Company in the principal amount of US\$197,864,523. Reference is also made to the announcement and the supplemental announcement of the Company dated 30 December 2022 and 22 March 2023 in relation to the proposed very substantial disposal and connected transaction of the Company, respectively (“**Announcements**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

THE NEW NOTES

As disclosed in Company’s announcement dated 3 January 2023, under the indenture governing the New Notes, the Company was due to redeem 5% of the original principal amount of the New Notes by 30 December 2022. In addition, the interest on the New Notes became due and payable on 30 December 2022. Under the indenture governing the New Notes, the Company had a grace period of 30 days to make the interest payment which had expired. The Company has not redeemed any of the New Notes or repaid the interests as at the date of this Announcement.

WRIT OF SUMMONS

The Board wishes to inform the Shareholders and potential investors of the Company that a writ of summons under the action number HCA 570 of 2023 was issued in the Court of First Instance of the High Court of The Hong Kong Special Administrative Region by Madison Pacific Trust Limited against the Company in respect of the New Notes. The writ claimed for, among other things, the following:

- (a) payment of the sum of US\$9,893,226.15, being the outstanding payment of at least 5% of US\$197,864,523 at a redemption price equal to par plus any accrued and unpaid interest and accrued semi-annual interest in respect of the notes of the Company;
- (b) payment of interest at the rate of 9.5% per annum on the sum of US\$9,239,065.78 from 31 December 2021 until payment;
- (c) injunction restraining the Company to, among other matters, convene the EGM and approve the Disposal;
- (d) interest;
- (e) costs; and
- (f) further relief as the court may think fit.

The Company continues to proactively engage with major holders of the New Notes with a view to exploring and implementing potential ways to address its liquidity issue, and to reach a consensual solution to best protect the interests of all its stakeholders. In the light of the latest development, the Company is also in the course of seeking legal advice in respect of the above matter. Further announcement(s) will be made by the Company as and when necessary.

Shareholders of the Company, noteholders and other investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
CEO and executive Director

Hong Kong, 17 April 2023

As at the date of this announcement, the executive Directors are Ms. Wang Hong, Ms. Liao Changxiang and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.